Search
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.
FM-VP4
go.drugbank.com/drugs/DB05449InvestigationalFM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.
Gadoquatrane
go.drugbank.com/drugs/DB33282Approvedin the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.
Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitorBromopride
go.drugbank.com/drugs/DB09018InvestigationalBromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
Categories: Dopamine D2 Receptor AntagonistsSynonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamideSelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalHowever, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step … Higher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue.
Picrotoxin
go.drugbank.com/drugs/DB00466ExperimentalAlthough it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Categories: Compounds used in a research, industrial, or household settingEslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalIt is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. … Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.[L36485]